Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death

Kidney International

Volumn 73, Issue 12, 2008, Pages 1385-1393

  Tejada, T ^a   Catanuto, P ^a   Ijaz, A ^a   Santos, J V ^a   Xia, X ^a   Sanchez, P ^a   Sanabria, N ^a   Lenz, O ^a   Elliot, S J ^a   Fornoni, A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

AKT; Cell death; Diabetic nephropathy; Insulin signaling; Podocytes

Indexed keywords

INSULIN; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA;

ALBUMINURIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CELL FUNCTION; CELL IMMORTALIZATION; CELL VIABILITY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; MOUSE; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

EID: 44449119048     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.109     Document Type: Article

References (44)

1. Li JJ, Kwak SJ, Jung DS et al. Podocyte biology in diabetic nephropathy. Kidney Int Suppl 2007; 106: S36-S42.
2. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
3. Dalla Vestra M, Masiero A, Roiter AM et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52: 1031-1035.
4. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
5. Steffes MW, Schmidt D, McCrery R et al. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001; 59: 2104-2113.
6. White KE, Bilous RW. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004; 19: 1437-1440.
7. White KE, Bilous RW, Marshall SM et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002; 51: 3083-3089.
8. Verzola D, Gandolfo MT, Ferrario F et al. Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int 2007; 72: 1262-1272.
9. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999; 42: 1341-1344.
10. Toyoda M, Najafian B, Kim Y et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007; 56: 2155-2160.
11. Susztak K, Raff AC, Schiffer M et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233.
12. Koya D, Haneda M, Nakagawa H et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439-447.
13. Bussolati B, Deregibus MC, Fonsato V et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 2005; 16: 1936-1947.
14. Logar CM, Brinkkoetter PT, Krofft RD et al. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007; 72: 489-498.
15. DeAngelis T, Chen J, Wu A et al. Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling. Oncogene 2006; 25: 32-42.
16. Lassak A, Del Valle L, Peruzzi F et al. Insulin receptor substrate 1 translocation to the nucleus by the human JC virus T-antigen. J Biol Chem 2002; 277: 17231-17238.
17. Valverde AM, Lorenzo M, Teruel T et al. Alterations in the insulin signaling pathway induced by immortalization and H-ras transformation of brown adipocytes. Endocrinology 1997; 138: 3195-3206.
18. Tang X, Powelka AM, Soriano NA et al. PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes. J Biol Chem 2005; 280: 22523-22529.
19. Coward RJ, Welsh GI, Yang J et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54: 3095-3102.
20. Reiter CE, Wu X, Sandirasegarane L et al. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes 2006; 55: 1148-1156.
21. Parvanova AI, Trevisan R, Iliev IP et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 2006; 55: 1456-1462.
22. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003; 284: F1138-F1144.
23. Breyer MD, Bottinger E, Brosius III FC et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 27-45.
24. Foster RR, Saleem MA, Mathieson PW et al. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 2005; 288: F48-F57.
25. Chuang TD, Guh JY, Chiou SJ et al. Phosphoinositide 3-kinase is required for high glucose-induced hypertrophy and p21WAF1 expression in LLC-PK1 cells. Kidney Int 2007; 71: 867-874.
26. Feliers D, Duraisamy S, Faulkner JL et al. Activation of renal signaling pathways in db/db mice with type 2 diabetes. Kidney Int 2001; 60: 495-504.
27. Szanto I, Kahn CR. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. Proc Natl Acad Sci USA 2000; 97: 2355-2360.
28. Morton GJ, Gelling RW, Niswender KD et al. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab 2005; 2: 411-420.
29. Fornoni A, Rosenzweig SA, Lenz O et al. Low insulin-like growth factor binding protein-2 expression is responsible for increased insulin receptor substrate-1 phosphorylation in mesangial cells from mice susceptible to glomerulosclerosis. Endocrinology 2006; 147: 3547-3554.
30. Fornoni A, Striker LJ, Zheng F et al. Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background. Diabetes 2002; 51: 499-505.
31. Coward RJ, Welsh GI, Koziell A et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes 2007; 56: 1127-1135.
32. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
33. White MF. Insulin signaling in health and disease. Science 2003; 302: 1710-1711.
34. Ghanim H, Aljada A, Daoud N et al. Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects. Diabetologia 2007; 50: 278-285.
35. Karl M, Potier M, Schulman IH et al. Autocrine activation of the local insulin-like growth factor I system is upregulated by estrogen receptor (ER)-independent estrogen actions and accounts for decreased ER expression in type 2 diabetic mesangial cells. Endocrinology 2005; 146: 889-900.
36. Foster RR, Hole R, Anderson K et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 2003; 284: F1263-F1273.
37. Moriwaki Y, Yamamoto T, Shibutani Y et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003; 52: 605-608.
38. Navarro JF, Mora-Fernandez C. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006; 17: 441-450.
39. Komers R, Lindsley JN, Oyama TT et al. Renal p38 MAP kinase activity in experimental diabetes. Lab Invest 2007; 87: 548-558.
40. Schmid H, Boucherot A, Yasuda Y et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006; 55: 2993-3003.
41. Marshall CB, Pippin JW, Krofft RD et al. Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 2006; 70: 1962-1973.
42. Yang HC, Ma LJ, Ma J et al. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69: 1756-1764.
43. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006; 70: 1223-1233.
44. Hojlund K, Glintborg D, Andersen NR et al. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes 2007; 57: 357-366.